Beam Therapeutics Outlines Long-term Strategy for Base Editing Programs in Sickle Cell Disease and Provides Preclinical Data Updates at ASH
12 déc. 2021 09h00 HE
|
Beam Therapeutics
CAMBRIDGE, Mass., Dec. 12, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today shared a...
Beam Therapeutics Reports Preclinical Data Highlighting Multiplex Base Editing Approach to Create Anti-CD5 CAR T-cell Investigational Therapies for T-Cell Malignancies
12 nov. 2021 07h00 HE
|
Beam Therapeutics
CAMBRIDGE, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced new...
Beam Therapeutics to Participate in the Jefferies 2021 Virtual London Healthcare Conference
11 nov. 2021 06h30 HE
|
Beam Therapeutics
CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics Provides Business and Pipeline Updates and Reports Third Quarter 2021 Financial Results
08 nov. 2021 06h00 HE
|
Beam Therapeutics
BEAM-101 IND Cleared by FDA for Evaluation as a Treatment for Sickle Cell Disease BEAM-102 IND-Enabling Studies Also Underway CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics...
Beam Therapeutics Appoints Healthcare Industry Leader John Maraganore, Ph.D., to its Board of Directors
08 nov. 2021 06h00 HE
|
Beam Therapeutics
CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics Announces Upcoming Preclinical Data Presentations at the American Society of Hematology Annual Meeting
04 nov. 2021 09h40 HE
|
Beam Therapeutics
Preclinical Data Demonstrates that BEAM-102 Makassar Base Editing Converts Sickle Hemoglobin to Functional Hemoglobin for Potential Treatment of Sickle Cell Disease New In Vivo Data Highlight Novel...
Beam Therapeutics to Participate in the Jefferies Gene Therapy/Editing Summit
20 oct. 2021 06h30 HE
|
Beam Therapeutics
CAMBRIDGE, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics Announces Preclinical Data Highlighting Base Editing Approach to Correct a Glycogen Storage Disease Type Ia Disease-Causing Mutation
19 oct. 2021 06h30 HE
|
Beam Therapeutics
CAMBRIDGE, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported new...
Beam Therapeutics to Present Preclinical Data Highlighting Potential of CAR T Multiplex Base Editing Approach Targeting CD5 at 2021 SITC Annual Meeting
01 oct. 2021 08h44 HE
|
Beam Therapeutics
CAMBRIDGE, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics to Participate in the Chardan Virtual 5th Annual Genetic Medicines Conference
28 sept. 2021 06h30 HE
|
Beam Therapeutics
CAMBRIDGE, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...